LAUSR

Purpose of ReviewIn this review, we will address the cardioprotective effect of low-dose radiation (LDR) on chemotherapeutic agents.Recent FindingsCancer has become the most important cause of death in the world, and the morbidity and mortality are gradually increased. The application of anti-tumor drugs is an important therapeutic tool for cancer therapy at present, while its potential cardiotoxicity cannot be ignored. How to prevent and reduce the occurrence of cardiotoxicities needs further exploration.SummaryLDR induces an adaptive or hormetic response in cells and tissues, showing a tolerance to subsequently high dose of radiation- or chemical-induced damage in vitro and in vivo. LDR may exert its cardioprotective effects through different mechanisms, such as stimulating the proliferation of normal cells during anti-tumor therapy, enhancing anti-tumor immunity, stimulating antioxidative functions in normal tissues, activating DNA damage repair system, and improving metabolic function in normal tissues. Therefore, there may be a potential to apply LDR as an adjunct to myocardial protection for anti-tumor therapy.